OpenURL Connection Search

Select item for more details and to access through your institution.

Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice.
Published in:
Journal of Clinical Investigation, 2012, v. 122, n. 5, p. 1717, doi. 10.1172/JCI60530
By:
- Takiishi, Tatiana;
- Korf, Hannelie;
- Van Belle, Tom L.;
- Robert, Sofie;
- Grieco, Fabio A.;
- Caluwaerts, Silvia;
- Galleri, Letizia;
- Spagnuolo, Isabella;
- Steidler, Lothar;
- Huynegem, Karolien Van;
- Demetter, Pieter;
- Wasserfall, Clive;
- Atkinson, Mark A.;
- Dotta, Francesco;
- Rottiers, Pieter;
- Gysemans, Conny;
- Mathieu, Chantal
Publication type:
Article
A first-in-human, open-label Phase 1b and a randomised, double-blind Phase 2a clinical trial in recent-onset type 1 diabetes with AG019 as monotherapy and in combination with teplizumab.
Published in:
Diabetologia, 2024, v. 67, n. 1, p. 27, doi. 10.1007/s00125-023-06014-2
By:
- Mathieu, Chantal;
- Wiedeman, Alice;
- Cerosaletti, Karen;
- Long, S. Alice;
- Serti, Elisavet;
- Cooney, Laura;
- Vermeiren, Joan;
- Caluwaerts, Silvia;
- Van Huynegem, Karolien;
- Steidler, Lothar;
- Blomme, Sven;
- Rottiers, Pieter;
- Nepom, Gerald T.;
- Herold, Kevan C.
Publication type:
Article
Intestinal Delivery of Proinsulin and IL-10 via Lactococcus lactis Combined With Low-Dose Anti-CD3 Restores Tolerance Outside the Window of Acute Type 1 Diabetes Diagnosis.
Published in:
Frontiers in Immunology, 2020, v. 11, p. 1, doi. 10.3389/fimmu.2020.01103
By:
- Cook, Dana P.;
- Cunha, João Paulo Monteiro Carvalho Mori;
- Martens, Pieter-Jan;
- Sassi, Gabriele;
- Mancarella, Francesca;
- Ventriglia, Giuliana;
- Sebastiani, Guido;
- Vanherwegen, An-Sofie;
- Atkinson, Mark A.;
- Van Huynegem, Karolien;
- Steidler, Lothar;
- Caluwaerts, Silvia;
- Rottiers, Pieter;
- Teyton, Luc;
- Dotta, Francesco;
- Gysemans, Conny;
- Mathieu, Chantal
Publication type:
Article
Oral Delivery of Glutamic Acid Decarboxylase (GAD)-65 and IL10 by Lactococcus lactis Reverses Diabetes in Recent-Onset NOD Mice.
Published in:
Diabetes, 2014, v. 63, n. 8, p. 2876, doi. 10.2337/db13-1236
By:
- Robert, Sofie;
- Gysemans, Conny;
- Tatiana Takiishi;
- Korf, Hannelie;
- Spagnuolo, Isabella;
- Sebastiani, Guido;
- Van Huynegem, Karolien;
- Steidler, Lothar;
- Caluwaerts, Silvia;
- Demetter, Pieter;
- Wasserfall, Clive H.;
- Atkinson, Mark A.;
- Dotta, Francesco;
- Rottiers, Pieter;
- Van Belle, Tom L.;
- Mathieu, Chantal
Publication type:
Article

Found: 4

Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice.

A first-in-human, open-label Phase 1b and a randomised, double-blind Phase 2a clinical trial in recent-onset type 1 diabetes with AG019 as monotherapy and in combination with teplizumab.

Intestinal Delivery of Proinsulin and IL-10 via Lactococcus lactis Combined With Low-Dose Anti-CD3 Restores Tolerance Outside the Window of Acute Type 1 Diabetes Diagnosis.

Oral Delivery of Glutamic Acid Decarboxylase (GAD)-65 and IL10 by Lactococcus lactis Reverses Diabetes in Recent-Onset NOD Mice.